Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical proof of concept study of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT)

Next Previous
Trial Profile

A clinical proof of concept study of Atavistik Bio's oral allosteric AKT1-selective inhibitor for Hereditary Hemorrhagic Telangiectasia (HHT)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Small molecules (Primary)
  • Indications Hereditary haemorrhagic telangiectasia
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 09 Jan 2026 New trial record
  • 18 Dec 2025 According to Atavistik Bio media release, the company anticipates initiating its clinical trial in HHT in 1H 2026. The company has raised a $120 million Series B financing which will support this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top